Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Study of Multivalent Group B Streptococcus Vaccine in Healthy Adults
NCT03170609Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jun 2017
- Primary completion
- Jun 2018
- Modality
- Split/Subunit Vaccines, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of GBS6 in group B streptococcal infection (7 arms), sponsored by Pfizer. Primary endpoints: Percentage of Participants With Clinical Laboratory Abnormalities at 1-Week After Vaccination as Measured by FDA Grade, Percentage of Participants With Local Reactions by Maximum Severity Within 14 Days After Vaccination and 4 more. Started Jun 2017; status: completed.
02
Drugs
GBS6
03
Conditions
group B streptococcal infection
Beyond the preview
Go deeper on NCT03170609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03170609.